About Alzheon
What we do
Our company
Founded in 2013 by Martin Tolar, MD, PhD, Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders. We develop these disease-modifying treatments by leveraging our expertise in inhibiting protein misfolding and aggregation.
Alzheon’s valiltramiprosate/ALZ-801 is a late-stage, investigational oral anti-amyloid treatment. We recently completed Phase 3 testing of valiltramiprosate in early symptomatic Alzheimer’s disease.
Development of valiltramiprosate is based on more than a decade of Alzheon research into the biology of Alzheimer’s disease.
Using our pioneering precision medicine approach, we are initially focusing development on the highest-risk patients – those with two copies of the APOE4 gene (APOE4/4 homozygotes). Future trials aim to expand treatment to patients with one copy of the APOE4 gene.
Who we are
Our experienced team
We are a passionate and highly experienced team of neuroscientists, pharmacologists, clinicians, drug developers and business leaders with a deep understanding of neurological and psychiatric disorders and a track record of successfully developing products to treat these diseases. We believe our team positions us to become a leading company developing disease modifying therapies for the treatment of neurodegenerative disorders.
Governance
Financial Conflict of Interest (FCOI) Policy
In compliance with federal regulations, Alzheon Inc. requires Investigators and Key Personnel participating in Public Health System (PHS) sponsored research to disclose Significant Financial Interests (SFI) that could reasonably bias the design, conduct, or reporting of the project.
Download the FCOI Policy (PDF)
For more information, visit the following links:
- 42 CFR Part 50 – Final rule (PDF)
- NIH FCOI
- NIH FCOI FAQs
- NIH FCOI Tutorial
Point of contact: if you have questions about the Financial Conflict of Interest Policy or existing disclosures, please contact the designated Institutional Official at ap@alzheon.com.
